Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy

被引:121
作者
Hance, AJ
Lemiale, V
Izopet, J
Lecossier, D
Joly, V
Massip, P
Mammano, F
Descamps, D
Brun-Vézinet, F
Clavel, F
机构
[1] Hop Bichat Claude Bernard, INSERM U552, IMEA, F-75018 Paris, France
[2] Hop Bichat Claude Bernard, Serv Malad Infect & Trop A, F-75018 Paris, France
[3] Hop Bichat Claude Bernard, Virol Lab, F-75018 Paris, France
[4] Univ Purpan, Ctr Hosp, Toulouse, France
关键词
D O I
10.1128/JVI.75.14.6410-6417.2001
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Mutations in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase and protease that confer resistance to antiretroviral agents are usually accompanied by a reduction in the viral replicative capacity under drug-free conditions. Consequently, when antiretroviral treatment is interrupted in HIV-l-infected patients harboring drug-resistant virus, resistant quasi-species appear to be most often replaced within several weeks by wild-type virus. Using a real-time PCR-based technique for the selective quantification of resistant viral sequences in plasma, we have studied the kinetics of the switch from mutant to wild-type virus and evaluated the extent to which minority populations of resistant viruses not detected by genotyping persist in these individuals. Among 12 patients with viruses expressing the V82A or L90M resistance mutation who had undergone a 3-month interruption of therapy and for whom conventional genotyping had revealed an apparent total reconversion to wild-type virus, minority populations expressing these mutations, representing 0.1 to 21% of total virus, were still detectable in 9 cases. Kinetic studies demonstrated that viruses expressing resistance mutations could be detected for >5 months after the discontinuation of treatment in some patients. Most of the minority resistant genomes detected more than 3 months after the interruption of therapy carried only part of the mutations present in the resistant viruses prior to treatment interruption and appeared to result from the emergence of existing strains selected at earlier stages in the development of drug resistance, Thus, following the interruption of treatment, viral populations containing resistance mutations can persist for several months after the time when conventional genotyping techniques detect only wild-type virus. These populations include viral strains with only some of the resistance mutations initially present, strains that presumably express better fitness under drug-free conditions.
引用
收藏
页码:6410 / 6417
页数:8
相关论文
共 33 条
[1]   Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme [J].
Back, NKT ;
Nijhuis, M ;
Keulen, W ;
Boucher, CAB ;
Essink, BBO ;
vanKuilenburg, ABP ;
vanGennip, AH ;
Berkhout, B .
EMBO JOURNAL, 1996, 15 (15) :4040-4049
[2]   Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1 [J].
Bleiber, G ;
Munoz, M ;
Ciuffi, A ;
Meylan, P ;
Telenti, A .
JOURNAL OF VIROLOGY, 2001, 75 (07) :3291-3300
[3]  
Cha R S, 1992, PCR Methods Appl, V2, P14
[4]   The effects of internal primer-template mismatches on RT-PCR: HIV-1 model studies [J].
Christopherson, C ;
Sninsky, J ;
Kwok, S .
NUCLEIC ACIDS RESEARCH, 1997, 25 (03) :654-658
[5]   HIV POPULATION-DYNAMICS IN-VIVO - IMPLICATIONS FOR GENETIC-VARIATION, PATHOGENESIS, AND THERAPY [J].
COFFIN, JM .
SCIENCE, 1995, 267 (5197) :483-489
[6]   Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor [J].
Condra, JH ;
Holder, DJ ;
Schleif, WA ;
Blahy, OM ;
Danovich, RM ;
Gabryelski, LJ ;
Graham, DJ ;
Laird, D ;
Quintero, JC ;
Rhodes, A ;
Robbins, HL ;
Roth, E ;
Shivaprakash, M ;
Yang, T ;
Chodakewitz, JA ;
Deutsch, PJ ;
Leavitt, RY ;
Massari, FE ;
Mellors, JW ;
Squires, KE ;
Steigbigel, RT ;
Teppler, H ;
Emini, EA .
JOURNAL OF VIROLOGY, 1996, 70 (12) :8270-8276
[7]   IN-VIVO EMERGENCE OF HIV-1 VARIANTS RESISTANT TO MULTIPLE PROTEASE INHIBITORS [J].
CONDRA, JH ;
SCHLEIF, WA ;
BLAHY, OM ;
GABRYELSKI, LJ ;
GRAHAM, DJ ;
QUINTERO, JC ;
RHODES, A ;
ROBBINS, HL ;
ROTH, E ;
SHIVAPRAKASH, M ;
TITUS, D ;
YANG, T ;
TEPPLER, H ;
SQUIRES, KE ;
DEUTSCH, PJ ;
EMINI, EA .
NATURE, 1995, 374 (6522) :569-571
[8]   Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors [J].
Croteau, G ;
Doyon, L ;
Thibeault, D ;
McKercher, G ;
Pilote, L ;
Lamarre, D .
JOURNAL OF VIROLOGY, 1997, 71 (02) :1089-1096
[9]   Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. [J].
Deeks, SG ;
Wrin, T ;
Liegler, T ;
Hoh, R ;
Hayden, M ;
Barbour, JD ;
Hellmann, NS ;
Petropoulos, CJ ;
McCune, JM ;
Hellerstein, MK ;
Grant, RM .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (07) :472-480
[10]   Reduction in human immunodeficiency virus type 1 mutations associated with drug resistance after initiating new therapeutic regimens in pretreated patients [J].
Devereux, HL ;
Loveday, C ;
Youle, M ;
Sabin, CA ;
Burke, A ;
Johnson, MA .
JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (05) :1804-1807